Cipla Q3 profit rises about 7% to Rs401 crore
Bengaluru: Cipla Ltd, India’s fourth-largest drugmaker by revenue, said third-quarter net profit rose 7% on strong domestic sales, but fell short of analysts’ estimates.
Net profit attributable to shareholders climbed to Rs401 crore ($62.54 million) in the quarter ended on 31 December, from Rs375 crore a year earlier.
That compared with an average estimate of Rs444 crore in profit drawn from 18 analysts polled by Thomson Reuters I/B/E/S.
Including a one-off positive impact of Rs107 crore due to recalculation of deferred tax assets and liabilities on account of the tax reforms in the United States, profit rose about 25% from a year earlier, the company said.
Revenue from India, its biggest market, rose 15% to Rs1,601 crore. Domestic revenue accounted for more than a third of the total revenue, which rose 7% to Rs3,914 crore.
Revenue from North America fell 2% due to ongoing pricing pressures in the generics market because of increased competition.
At 2.29pm, Cipla shares were down 0.74% to Rs561.45 on BSE. Reuters
- Wipro falls nearly 5% as brokerages cut target price on weak Q4 results
- A good competitor is good for HUL: Sanjiv Mehta
- Breaking taboos is becoming good for business in India
- Our core strategy is working and showing healthy growth: Wipro CEO Abidali Neemuchwala
- Contract manufacturers of global firms to launch own TV brands